Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy

25 Jan 2018

Abstract excerpt

Diminished overall survival rate of non-Hodgkin lymphoma (NHL) patients treated with a combination regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) has been recently linked to recurrent somatic mutations activating FOXO1. Despite of the clinical relevance of this finding, the molecular mechanism driving resistance to R-CHOP therapy remains largely unknown. Herein, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to FOXO transcription factor regulation
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29721381
DOI: 10.1080/2162402x.2017.1423183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapyPMID 29721381Read ↗

Analysis of FOXO1 mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

The discrete roles of individual FOXO transcription factor family members in B-cell malignanciesSemantic proximity Read ↗

Nuclear FOXO1 promotes lymphomagenesis in germinal center B cellsSemantic proximity Read ↗

Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.Semantic proximity Read ↗

Clever cancer strategies with FoxO transcription factorsSemantic proximity Read ↗

The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapySemantic proximity Read ↗

Role and regulation of FOXO3a: new insights into breast cancer therapySemantic proximity Read ↗

Role of FoxO Proteins in Cellular Response to Antitumor AgentsSemantic proximity Read ↗

Deciphering the roles of FOXO1 in human neoplasmsSemantic proximity Read ↗

An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiationSemantic proximity Read ↗

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodiesSemantic proximity Read ↗

IRF8 regulates efficacy of therapeutic anti‐CD20 monoclonal antibodiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.